Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

ISRG has fallen 40% from recent highs as da Vinci robot sales growth slows under pressure from MDT and JNJ competition, according to The Motley Fool. The decline marks a sharp reversal from the robotic surgery leader's post-pandemic momentum.

Despite the sales headwind, ISRG's business model leans heavily on recurring revenue—parts and services account for 75% of total revenue, providing an annuity-like cash stream less vulnerable to one-time equipment sales volatility. The company's valuation metrics now sit below five-year averages, a shift that may attract growth investors willing to stomach historical price swings.

The competitive threat from MDT and JNJ in robotic surgery is intensifying, eroding ISRG's dominance in procedure volumes and limiting pricing power. However, the installed base of da Vinci systems continues to generate predictable consumables and maintenance revenue even as new placements slow. AI-driven enhancements to the platform represent a potential catalyst for procedure growth and margin expansion.